Status:

TERMINATED

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Lead Sponsor:

Solvay Pharmaceuticals

Conditions:

Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Eligibility:

All Genders

65-90 years

Phase:

PHASE3

Brief Summary

This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.

Eligibility Criteria

Inclusion

  • Diagnosis of dementia of the Alzheimer's type

Exclusion

  • History of seizure disorder
  • Clinically significant electrocardiogram (ECG)
  • Clinical or radiological evidence of stroke, vascular dementia or dementia due to substance abuse, or head trauma

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2008

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00160147

Start Date

December 1 2005

End Date

January 1 2008

Last Update

February 9 2015

Active Locations (51)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (51 locations)

1

Site 912

Phoenix, Arizona, United States

2

Site 902

Carson, California, United States

3

Site 903

Long Beach, California, United States

4

Site 911

Pasadena, California, United States